In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At AHA, A Debate Over Drug-Eluting Stents

Executive Summary

If any medical device should confirm the role of clinical trials in influencing adoption, it's drug-eluting stents. But a debate at the American Heart Association meeting made clear that evidence-based medicine wasn't the ony side of the story. Beyond simple resistance to change, real-world issues--concerns over costs and unforeseen future consequences, among the most notable--often argue more strongly to physicians.

You may also be interested in...



Challenges & Opportunities for CABG Surgery

Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.

AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness

Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.

Business & Technology Briefs (01/2007)

A short summary of recent market and product developments in Interventional Cardiology, Spine Surgery, and Aesthetics, including: DES Safety Panel Weighs the Evidence; Percutaneous Lubar Fusion, and New Dermal Fillers.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel